Cardiac events among a cohort of 17,389 patients receiving cancer chemotherapy: short and long term implications
Approximately 50% of patients assigned to cancer chemotherapy developed CVD<sub>S</sub>, heralding a particularly high risk of mortality over the next 12 months. Both CVD<sub>A</sub> and CVD<sub>S</sub> are associated with substantial increases in mortality rates relative to those in CVD<sup>-</sup> patients. This increased risk merits close individual monitoring.
Authors
- John D. Horowitz (ORCID: https://orcid.org/0000-0001-6883-0703)
- Nicolle H. Packer (ORCID: https://orcid.org/0000-0002-7532-4021)
- Aaron L. Sverdlov (ORCID: https://orcid.org/0000-0003-2539-8038)
- Bogda Koczwara (ORCID: https://orcid.org/0000-0002-1201-1642)
- Robyn A. Clark (ORCID: https://orcid.org/0000-0002-5063-2618)
- Saifei Liu
Institutions
- Flinders University (AU)
- John Hunter Hospital (AU)
- Hunter Medical Research Institute (AU)
- Basil Hetzel Institute (AU)
- Women's and Children's Health Network (AU)
- Calvary Mater Newcastle Hospital (AU)
- The University of Adelaide (AU)
Publication Details
- Journal
- Cardio-Oncology
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1186/s40959-024-00269-3
- Citations
- 2
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.80